Wang H - Search Results

1

18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model.

Song SL, Deng C, Wen LF, Liu JJ, Wang H, Feng D, Wong CY, Huang G. Song SL, et al. Among authors: wang h. Nucl Med Biol. 2010 Apr;37(3):327-33. doi: 10.1016/j.nucmedbio.2009.12.002. Epub 2010 Jan 15. Nucl Med Biol. 2010. PMID: 20346872

2

Application of support vector machine in cancer diagnosis.

Wang H, Huang G. Wang H, et al. Med Oncol. 2011 Dec;28 Suppl 1:S613-8. doi: 10.1007/s12032-010-9663-4. Epub 2010 Sep 15. Med Oncol. 2011. PMID: 20842538

3

Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer.

Wang H, Fu HL, Li JN, Zhou RJ, Hui Gu Z, Wu JC, Huang G. Wang H, et al. Clin Imaging. 2008 Jan-Feb;32(1):32-7. doi: 10.1016/j.clinimag.2007.07.010. Clin Imaging. 2008. PMID: 18164392

4

Dynamic observation of the radiosensitive effect of irisquinone on rabbit VX2 lung transplant tumors by using fluorine-18-deoxyglucose positron emission tomography/computed tomography.

Xu H, Sun G, Wang H, Yue Q, Tang H, Wu Q. Xu H, et al. Among authors: wang h. Nucl Med Commun. 2013 Mar;34(3):220-8. doi: 10.1097/MNM.0b013e32835d3730. Nucl Med Commun. 2013. PMID: 23276827

5

Fluorine-18-deoxyglucose positron emission tomography/computed tomography with Ki67 and GLUT-1 immunohistochemistry for evaluation of the radiosensitization effect of oleanolic acid on C6 rat gliomas.

Zhang Y, Xu H, Wang H, Yu W, Zhao X, Xue Y. Zhang Y, et al. Among authors: wang h. Nucl Med Commun. 2015 Jan;36(1):21-7. doi: 10.1097/MNM.0000000000000211. Nucl Med Commun. 2015. PMID: 25222909

6

Correlation between ¹⁸F-FDG uptake and the expression of glucose transporter-1 and hypoxia-inducible factor-1α in transplanted VX2 tumors.

Xu H, Li B, Yu W, Wang H, Zhao X, Yao Y, Huang D. Xu H, et al. Among authors: wang h. Nucl Med Commun. 2013 Oct;34(10):953-8. doi: 10.1097/MNM.0b013e328364a9e2. Nucl Med Commun. 2013. PMID: 23887273

7

Dedifferentiation of differentiated thyroid carcinoma cell line FTC-133 is enhanced by 131I pretreatment.

Feng F, Wang H, Fu H, Wu S, Ye Z, Chen S, Li J. Feng F, et al. Among authors: wang h. Nucl Med Biol. 2011 Oct;38(7):1053-8. doi: 10.1016/j.nucmedbio.2011.03.001. Epub 2011 Apr 21. Nucl Med Biol. 2011. PMID: 21982575

8

Re-induction of cell differentiation and (131)I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection.

Feng F, Wang H, Hou S, Fu H. Feng F, et al. Among authors: wang h. Nucl Med Biol. 2012 Nov;39(8):1261-5. doi: 10.1016/j.nucmedbio.2012.07.004. Epub 2012 Aug 14. Nucl Med Biol. 2012. PMID: 22898315

9

The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer.

Wang H, Fu HL, Li JN, Zou RJ, Gu ZH, Wu JC. Wang H, et al. Clin Imaging. 2009 Jan-Feb;33(1):49-54. doi: 10.1016/j.clinimag.2008.06.024. Clin Imaging. 2009. PMID: 19135930

10

The study of influence factors on (131)I treatment of differentiated thyroid carcinoma with lymph node metastases.

Ye ZY, Wang H, Fu HL, Li JN, Zou RJ, Gu ZH, Wu JC. Ye ZY, et al. Among authors: wang h. Clin Imaging. 2009 May-Jun;33(3):221-5. doi: 10.1016/j.clinimag.2008.09.006. Clin Imaging. 2009. PMID: 19411029

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

151,965 results

Search Page

Filters